CLL-clear sailing ahead for many, while rough waters remain for some

Affiliations

¹ Leukemia/Bone Marrow Transplant Program of British Columbia, Canada; Division of Hematology, Vancouver General Hospital and British Columbia Cancer Agency, Canada; University of British Columbia, Canada. Electronic address: ctoze@bccancer.bc.ca.
² Leukemia/Bone Marrow Transplant Program of British Columbia, Canada; Lymphoma Tumour Group, Divisions of Hematology and Medical Oncology, British Columbia Cancer Agency, Canada; University of British Columbia, Canada.

Editorial

Cynthia L Toze et al. Leuk Res. 2014 Oct.

. 2014 Oct;38(10):1154-5.

doi: 10.1016/j.leukres.2014.07.008. Epub 2014 Aug 12.

¹ Leukemia/Bone Marrow Transplant Program of British Columbia, Canada; Division of Hematology, Vancouver General Hospital and British Columbia Cancer Agency, Canada; University of British Columbia, Canada. Electronic address: ctoze@bccancer.bc.ca.
² Leukemia/Bone Marrow Transplant Program of British Columbia, Canada; Lymphoma Tumour Group, Divisions of Hematology and Medical Oncology, British Columbia Cancer Agency, Canada; University of British Columbia, Canada.

No abstract available

Comment on

Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Chavez JC, et al. Leuk Res. 2014 Oct;38(10):1165-72. doi: 10.1016/j.leukres.2014.04.006. Epub 2014 Apr 28. Leuk Res. 2014. PMID: 24889511 Free PMC article.